相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。BRD4 inhibition induces synthetic lethality in ARID2-deficient hepatocellular carcinoma by increasing DNA damage
Dan-Dan He et al.
ONCOGENE (2022)
Thymoquinone Radiosensitizes Human Colorectal Cancer Cells in 2D and 3D Culture Models
Samar Al Bitar et al.
CANCERS (2022)
Achieving clinical success with BET inhibitors as anti-cancer agents
Tatiana Shorstova et al.
BRITISH JOURNAL OF CANCER (2021)
Estimated Projection of US Cancer Incidence and Death to 2040
Lola Rahib et al.
JAMA NETWORK OPEN (2021)
Pancreatic Cancer: A Review
Wungki Park et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer
Aubrey L. Miller et al.
CANCERS (2021)
The combination of BET and PARP inhibitors is synergistic in models of cholangiocarcinoma
Samuel C. Fehling et al.
CANCER LETTERS (2020)
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial
Eva Versteijne et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma
Aaron J. Grossberg et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
BET inhibition therapy counteracts cancer cell survival, clonogenic potential and radioresistance mechanisms in rhabdomyosarcoma cells
Simona Camero et al.
CANCER LETTERS (2020)
BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy
Catia Mio et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors
Aubrey L. Miller et al.
EBIOMEDICINE (2019)
Bromodomains: a new target class for drug development
Andrea G. Cochran et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
RAD51 is a potential marker for prognosis and regulates cell proliferation in pancreatic cancer
Xiaomeng Zhang et al.
CANCER CELL INTERNATIONAL (2019)
The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer
Andrew J. Wilson et al.
GYNECOLOGIC ONCOLOGY (2018)
BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer
Xiangyi Li et al.
CELL REPORTS (2018)
BRD4 and Cancer: going beyond transcriptional regulation
Benedetta Donati et al.
MOLECULAR CANCER (2018)
Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition
Lu Yang et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer
Sergey Karakashev et al.
CELL REPORTS (2017)
BET inhibitors: a novel epigenetic approach
D. B. Doroshow et al.
ANNALS OF ONCOLOGY (2017)
The BET bromodomain inhibitor JQ1 radiosensitizes non-small cell lung cancer cells by upregulating p21
Jian Wang et al.
CANCER LETTERS (2017)
The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models
P. L. Garcia et al.
ONCOGENE (2016)
Clinical development of new drug-radiotherapy combinations
Ricky A. Sharma et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair
Tasneem Kausar et al.
NEOPLASIA (2015)
An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma
Maria Giuseppina Baratta et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
An epigenomic approach to therapy for tamoxifen-resistant breast cancer
Qin Feng et al.
CELL RESEARCH (2014)
BET Bromodomain Inhibitors Block Growth of Pancreatic Cancer Cells in Three-Dimensional Collagen
Vaibhav Sahai et al.
MOLECULAR CANCER THERAPEUTICS (2014)
The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition
Junwei Shi et al.
MOLECULAR CELL (2014)
Neoadjuvant FOLFIRINOX for Borderline Resectable Pancreas Cancer: A New Treatment Paradigm?
Kathleen K. Christians et al.
ONCOLOGIST (2014)
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Jakob Loven et al.
CELL (2013)
Sensitization of Pancreatic Cancer to Chemoradiation by the Chk1 Inhibitor MK8776
Carl G. Engelke et al.
CLINICAL CANCER RESEARCH (2013)
Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins
William W. Lockwood et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Selective inhibition of BET bromodomains
Panagis Filippakopoulos et al.
NATURE (2010)
AHPBA/SSO/SSAT Consensus Conference on Resectable and Borderline Resectable Pancreatic Cancer: Rationale and Overview of the Conference
Jean-Nicolas Vauthey et al.
ANNALS OF SURGICAL ONCOLOGY (2009)
National failure to operate on early stage pancreatic cancer
Karl Y. Bilimoria et al.
ANNALS OF SURGERY (2007)
Clonogenic assay of cells in vitro
Nicolaas A. P. Franken et al.
NATURE PROTOCOLS (2006)
Locally advanced pancreatic cancer
CG Willett et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas
VK Mehta et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2001)
DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma
H Maacke et al.
ONCOGENE (2000)
分享论文
